Honglin Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/52149/publications.pdf

Version: 2024-02-01

272 papers	33,673 citations	6613 79 h-index	4432 172 g-index
291 all docs	291 docs citations	291 times ranked	41824 citing authors

#	Article	IF	Citations
1	The Dynamics of Social Assistance in the Informal Economy: Empirical Evidence from Urban China. Journal of Social Policy, 2023, 52, 840-863.	1.1	1
2	Potential Antiviral Target for SARS-CoV-2: A Key Early Responsive Kinase during Viral Entry. CCS Chemistry, 2022, 4, 112-121.	7.8	6
3	Gender convergence or divergence in the relationship between late-life depression and multiple stressors: evidence from a national survey in China. Journal of Women and Aging, 2022, 34, 196-209.	1.0	4
4	Widowhood and depression among Chinese older adults: examining coping styles and perceptions of aging as mediators and moderators. Aging and Mental Health, 2022, 26, 1161-1169.	2.8	5
5	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine, 2022, 75, 103762.	6.1	32
6	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. Vaccines, 2022, 10, 72.	4.4	13
7	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. Vaccines, 2022, 10, 160.	4.4	33
8	SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerging Microbes and Infections, 2022, 11, 277-283.	6.5	308
9	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 2022, 602, 676-681.	27.8	1,038
10	Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases, 2022, 75, e822-e826.	5.8	322
11	Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines. MSphere, 2022, 7, e0091521.	2.9	9
12	Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test. Microbiology Spectrum, 2022, 10, e0099321.	3.0	3
13	Resilience building among Chinese family caregivers of older people with Parkinsonâ€™s disease in Shanghai. Health and Social Care in the Community, 2022, 30, .	1.6	1
14	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
15	Zoonotic attack: An underestimated threat of SARS-CoV-2?. Innovation(China), 2022, , 100242.	9.1	0
16	Studies on the Digital Inclusion Among Older Adults and the Quality of Lifeâ€”A Nanjing Example in China. Frontiers in Public Health, 2022, 10, .	2.7	5
17	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin, 2022, 67, 1372-1387.	9.0	54
18	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science, 2022, 377, 428-433.	12.6	113

#	Article	IF	Citations
19	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nature Communications, 2022, 13, .	12.8	22
20	Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking. Journal of the American Chemical Society, 2022, 144, 13146-13153.	13.7	32
21	Natural Transmission of Bat-like Severe Acute Respiratory Syndrome Coronavirus 2 Without Proline-Arginine-Arginine-Alanine Variants in Coronavirus Disease 2019 Patients. Clinical Infectious Diseases, 2021, 73, e437-e444.	5.8	62
22	Establishment of a rapid ELISPOT assay for influenza virus titration and neutralizing antibody detection. Journal of Medical Virology, 2021, 93, 3455-3464.	5.0	8
23	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature, 2021, 593, 418-423.	27.8	151
24	RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-Î²2. Nature Communications, 2021, 12, 1518.	12.8	42
25	Aptamer Blocking Strategy Inhibits SARSâ€CoVâ€2 Virus Infection. Angewandte Chemie - International Edition, 2021, 60, 10266-10272.	13.8	144
26	InnenrÃ¼cktitelbild: Aptamer Blocking Strategy Inhibits SARSâ€CoVâ€2 Virus Infection (Angew. Chem.) Tj ETQq0 0 0 rgBT /Overlock 10	2.0	0
27	Aptamer Blocking Strategy Inhibits SARSâ€CoVâ€2 Virus Infection. Angewandte Chemie, 2021, 133, 10354-10360.	2.0	20
28	Association between primary caregiver type and mortality among Chinese older adults with disability: a prospective cohort study. BMC Geriatrics, 2021, 21, 268.	2.7	5
29	Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle. Journal of Virology, 2021, 95, .	3.4	14
30	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell, 2021, 184, 2618-2632.e17.	28.9	80
31	Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein. Nature Communications, 2021, 12, 2790.	12.8	26
32	Antigenic Drift of the Hemagglutinin from an Influenza A (H1N1) pdm09 Clinical Isolate Increases its Pathogenicity In Vitro. Virologica Sinica, 2021, 36, 1220-1227.	3.0	4
33	Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy. Journal of Hepatology, 2021, 74, 1315-1324.	3.7	29
34	Mammalian cells use the autophagy process to restrict avian influenza virus replication. Cell Reports, 2021, 35, 109213.	6.4	17
35	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 697074.	4.8	18
36	Effect of physical frailty on elder mistreatment in a national survey: examining psychological vulnerability, housework involvement, and financial independence as mediators. International Psychogeriatrics, 2021, , 1-11.	1.0	4

#	Article	IF	Citations
37	Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges. Npj Vaccines, 2021, 6, 95.	6.0	6
38	Cellular 5â€²-3â€² mRNA Exoribonuclease XRN1 Inhibits Interferon Beta Activation and Facilitates Influenza A Virus Replication. MBio, 2021, 12, e0094521.	4.1	10
39	Multiple basic amino acids in the cleavage site of H7N9 hemagglutinin contribute to high virulence in mice. Journal of Thoracic Disease, 2021, 13, 4650-4660.	1.4	2
40	Low dose inocula of SARS-CoV-2 Alpha variant transmits more efficiently than earlier variants in hamsters. Communications Biology, 2021, 4, 1102.	4.4	20
41	Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples. Diagnostics, 2021, 11, 1757.	2.6	27
42	Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters. Clinical Infectious Diseases, 2021, 72, e978-e992.	5.8	84
43	Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape. Journal of the American Chemical Society, 2021, 143, 21541-21548.	13.7	56
44	MENTAL HEALTH AND WELL-BEING OF EMPTY-NESTERS: A CHINESE URBAN CASE STUDY. The Hong Kong Journal of Social Work, 2021, 55, 19-38.	0.1	0
45	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant. Vaccines, 2021, 9, 1442.	4.4	18
46	Co-circulation of a Novel Dromedary Camel Parainfluenza Virus 3 and Middle East Respiratory Syndrome Coronavirus in a Dromedary Herd With Respiratory Tract Infections. Frontiers in Microbiology, 2021, 12, 739779.	3.5	4
47	Promises and pitfalls of integrating home-based health services into Shanghai's elder-care system. Ageing and Society, 2020, 40, 480-500.	1.7	5
48	Mental health and well-being in older women in China: implications from the Andersen model. BMC Geriatrics, 2020, 20, 254.	2.7	9
49	CUT&RUN detects distinct DNA footprints of RNA polymerase II near the transcription start sites. Chromosome Research, 2020, 28, 381-393.	2.2	7
50	Viruses harness YxxÃ˜ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. Science Advances, 2020, 6, eaba7910.	10.3	40
51	PB1-F2 protein of highly pathogenic influenza A (H7N9) virus selectively suppresses RNA-induced NLRP3 inflammasome activation through inhibition of MAVS-NLRP3 interaction. Journal of Leukocyte Biology, 2020, 108, 1655-1663.	3.3	27
52	Infection of bat and human intestinal organoids by SARS-CoV-2. Nature Medicine, 2020, 26, 1077-1083.	30.7	441
53	Virus subtype-specific suppression of MAVS aggregation and activation by PB1-F2 protein of influenza A (H7N9) virus. PLoS Pathogens, 2020, 16, e1008611.	4.7	21
54	Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infectious Diseases, The, 2020, 20, 565-574.	9.1	2,704

#	Article	IF	Citations
55	Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clinical Infectious Diseases, 2020, 71, 2428-2446.	5.8	839
56	The effect of gender role attitudes on the self-efficacy of the older adults: based on data from the third wave Survey of Chinese Womenâ€™s social status. Asia Pacific Journal of Social Work and Development, 2020, 30, 273-287.	1.0	1
57	A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, The, 2020, 395, 514-523.	13.7	7,120
58	Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerging Microbes and Infections, 2020, 9, 837-842.	6.5	270
59	Circulating Epsteinâ€Barr virus microRNAs BART7â€3p and BART13â€3p as novel biomarkers in nasopharyngeal carcinoma. Cancer Science, 2020, 111, 1711-1723.	3.9	28
60	Title is missing!. , 2020, 16, e1008611.		0
61	Title is missing!. , 2020, 16, e1008611.		0
62	Title is missing!. , 2020, 16, e1008611.		0
63	Title is missing!. , 2020, 16, e1008611.		0
64	Medical and housing needs of older part-time migrant workers and the role of government: the Linyi model in China. Asia Pacific Journal of Social Work and Development, 2019, 29, 236-247.	1.0	0
65	Epstein-Barr Virus BART Long Non-coding RNAs Function as Epigenetic Modulators in Nasopharyngeal Carcinoma. Frontiers in Oncology, 2019, 9, 1120.	2.8	44
66	SMRT sequencing revealed the diversity and characteristics of defective interfering RNAs in influenza A (H7N9) virus infection. Emerging Microbes and Infections, 2019, 8, 662-674.	6.5	24
67	Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Oral Oncology, 2019, 93, 85-90.	1.5	14
68	Conventional and Novel Diagnostic Biomarkers and Approaches for Detection of Nasopharyngeal Carcinoma. , 2019, , 129-153.		1
69	The PB2 Polymerase Host Adaptation Substitutions Prime Avian Indonesia Sub Clade 2.1 H5N1 Viruses for Infecting Humans. Viruses, 2019, 11, 292.	3.3	7
70	Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. MBio, 2019, 10, .	4.1	51
71	An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics, 2019, 9, 210-231.	10.0	37
72	Low population serum microneutralization antibody titer against the predominating influenza A(H3N2) N121K virus during the severe influenza summer peak of Hong Kong in 2017. Emerging Microbes and Infections, 2018, 7, 1-9.	6.5	15

#	Article	IF	Citations
73	Establishment and validation of a twoâ€step screening scheme for improved performance of serological screening of nasopharyngeal carcinoma. Cancer Medicine, 2018, 7, 1458-1467.	2.8	14
74	Rapid detection of MERS coronavirus-like viruses in bats: potential for tracking MERS coronavirus transmission and animal origin. Emerging Microbes and Infections, 2018, 7, 1-7.	6.5	24
75	Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding. Journal of Infectious Diseases, 2018, 218, 197-207.	4.0	80
76	Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	13
77	Rapid identification of imported influenza viruses at Xiamen International Airport via an active surveillance program. Clinical Microbiology and Infection, 2018, 24, 289-294.	6.0	9
78	EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-ÎºB and Erk1/2 pathways. Journal of Experimental and Clinical Cancer Research, 2018, 37, 283.	8.6	66
79	Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant. Emerging Infectious Diseases, 2018, 24, 2241-2250.	4.3	167
80	Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nature Communications, 2018, 9, 4663.	12.8	106
81	Identification of different hemagglutinin isoforms of influenza A virus H1N1. Rapid Communications in Mass Spectrometry, 2018, 32, 1372-1378.	1.5	3
82	NF-ÎºB Signaling Regulates Epsteinâ€“Barr Virus BamHI-Q-Driven EBNA1 Expression. Cancers, 2018, 10, 119.	3.7	13
83	Antiviral activity of doubleâ€stranded RNAâ€binding protein PACT against influenza A virus mediated via suppression of viral RNA polymerase. FASEB Journal, 2018, 32, 4380-4393.	0.5	14
84	Differentiated human airway organoids to assess infectivity of emerging influenza virus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6822-6827.	7.1	215
85	Structural Basis for the Broad, Antibody-Mediated Neutralization of H5N1 Influenza Virus. Journal of Virology, 2018, 92, .	3.4	8
86	A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Journal of Virology, 2017, 91, .	3.4	6
87	Divergent Requirement of Fc-FcÎ³ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies. Journal of Virology, 2017, 91, .	3.4	8
88	An NS-segment exonic splicing enhancer regulates influenza A virus replication in mammalian cells. Nature Communications, 2017, 8, 14751.	12.8	51
89	A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine, 2017, 9, .	12.4	65
90	The role of nuclear NS1 protein in highly pathogenic H5N1 influenza viruses. Microbes and Infection, 2017, 19, 587-596.	1.9	15

#	Article	IF	Citations
91	An Ambiguous Sense of Professional Identity: Community-Based Caregivers for Older Adults in China. Ageing International, 2017, 42, 236-250.	1.3	7
92	Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection. Chest, 2017, 151, 1069-1080.	0.8	95
93	Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. Journal of General Virology, 2017, 98, 946-954.	2.9	53
94	Bats host diverse parvoviruses as possible origin of mammalian dependoparvoviruses and source for batâ€“swine interspecies transmission. Journal of General Virology, 2017, 98, 3046-3059.	2.9	20
95	Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma. Oncotarget, 2017, 8, 42007-42019.	1.8	14
96	Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB/c mice. Oncotarget, 2017, 8, 91828-91840.	1.8	7
97	A highly specific rapid antigen detection assay for on-site diagnosis of MERS. Journal of Infection, 2016, 73, 82-84.	3.3	39
98	Hemagglutinin of influenza A virus binds specifically to cell surface nucleolin and plays a role in virus internalization. Virology, 2016, 494, 78-88.	2.4	42
99	Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice. Vaccine, 2016, 34, 2627-2633.	3.8	5
100	NF-Î°B Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma. Journal of Virology, 2016, 90, 6475-6488.	3.4	73
101	Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir. MAbs, 2016, 8, 1156-1166.	5.2	10
102	Complete Genome Sequence of Influenza Virus H9N2 Associated with a Fatal Outbreak among Chickens in Dubai. Genome Announcements, 2016, 4, .	0.8	8
103	MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nature Microbiology, 2016, 1, 16004.	13.3	140
104	Human H7N9 virus induces a more pronounced pro-inflammatory cytokine but an attenuated interferon response in human bronchial epithelial cells when compared with an epidemiologically-linked chicken H7N9 virus. Virology Journal, 2016, 13, 42.	3.4	17
105	Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice. Vaccine, 2016, 34, 2362-2370.	3.8	34
106	Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics. Journal of Virology, 2016, 90, 2690-2701.	3.4	28
107	Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial. Lancet Infectious Diseases, The, 2016, 16, 209-218.	9.1	75
108	Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. Journal of General Virology, 2016, 97, 1807-1817.	2.9	59

#	Article	IF	Citations
109	Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine. Oncotarget, 2016, 7, 81012-81025.	1.8	9
110	Privileged policies versus lack of care and engagement: the lives of retired veteran cadres in a residential community of Jinan Municipal Party Committee, China. Asia Pacific Journal of Social Work and Development, 2015, 25, 239-249.	1.0	2
111	The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice. PLoS ONE, 2015, 10, e0135999.	2.5	12
112	A phylogenetically distinct Middle East respiratory syndrome coronavirus detected in a dromedary calf from a closed dairy herd in Dubai with rising seroprevalence with age. Emerging Microbes and Infections, 2015, 4, 1-5.	6.5	24
113	The measurement and implication of the older peopleâ€™s social function in the community: a Shanghai experience. Asia Pacific Journal of Social Work and Development, 2015, 25, 225-238.	1.0	3
114	Older adults in the community: capacities and engagement for ageing in place. Asia Pacific Journal of Social Work and Development, 2015, 25, 183-185.	1.0	2
115	Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection. Archives of Virology, 2015, 160, 777-786.	2.1	20
116	Characterization of Complementary Determinant Region 3Î´ in Human MutS Homologue 2â€Specific Î³Î´ T Cells. Scandinavian Journal of Immunology, 2015, 81, 121-128.	2.7	7
117	A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerging Microbes and Infections, 2015, 4, 1-5.	6.5	74
118	Treatment With Lopinavir/Ritonavir or Interferon-Î²1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. Journal of Infectious Diseases, 2015, 212, 1904-1913.	4.0	572
119	Cross-species transmission and emergence of novel viruses from birds. Current Opinion in Virology, 2015, 10, 63-69.	5.4	74
120	Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes. Vaccine Journal, 2015, 22, 1235-1243.	3.1	19
121	An A14U Substitution in the 3â€² Noncoding Region of the M Segment of Viral RNA Supports Replication of Influenza Virus with an NS1 Deletion by Modulating Alternative Splicing of M Segment mRNAs. Journal of Virology, 2015, 89, 10273-10285.	3.4	19
122	Severe Acute Respiratory Syndrome (SARS) Coronavirus ORF8 Protein Is Acquired from SARS-Related Coronavirus from Greater Horseshoe Bats through Recombination. Journal of Virology, 2015, 89, 10532-10547.	3.4	172
123	CRISPR/Cas9-mediated genome editing of Epsteinâ€“Barr virus in human cells. Journal of General Virology, 2015, 96, 626-636.	2.9	155
124	Circulating <scp>E</scp>psteinâ€“<scp>B</scp>arr virus micro<scp>RNA</scp>s mi<scp>Râ€BART7</scp> and mi<scp>Râ€BART13</scp> as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. International Journal of Cancer, 2015, 136, E301-12.	5.1	107
125	Outbreaks of highly pathogenic avian influenza H5N1 clade 2.3.2.1c in hunting falcons and kept wild birds in Dubai implicate intercontinental virus spread. Journal of General Virology, 2015, 96, 3212-3222.	2.9	31
126	Avian Influenza A H7N9 Virus Induces Severe Pneumonia in Mice without Prior Adaptation and Responds to a Combination of Zanamivir and COX-2 Inhibitor. PLoS ONE, 2014, 9, e107966.	2.5	35

#	Article	IF	Citations
127	Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013. International Journal of Infectious Diseases, 2014, 29, 254-258.	3.3	8
128	Targeted Activation of Human VÎ³9VÎ´2-T Cells Controls Epstein-Barr Virus-Induced B Cell Lymphoproliferative Disease. Cancer Cell, 2014, 26, 565-576.	16.8	115
129	The K526R substitution in viral protein PB2 enhances the effects of E627K on influenza virus replication. Nature Communications, 2014, 5, 5509.	12.8	155
130	Social assistance in Shanghai: Dynamics between social protection and informal employment. International Journal of Social Welfare, 2014, 23, 333-341.	1.7	11
131	An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus. Journal of Infectious Diseases, 2014, 209, 236-242.	4.0	111
132	Transmission of H7N9 influenza virus in mice by different infective routes. Virology Journal, 2014, 11, 185.	3.4	10
133	NF90 Exerts Antiviral Activity through Regulation of PKR Phosphorylation and Stress Granules in Infected Cells. Journal of Immunology, 2014, 192, 3753-3764.	0.8	44
134	Rapid adaptation of avian H7N9 virus in pigs. Virology, 2014, 452-453, 231-236.	2.4	20
135	Empowerment of Senior Citizens via the Learning of Information and Communication Technology. Ageing International, 2014, 39, 144-162.	1.3	12
136	Unique reassortant of influenza A(H7N9) virus associated with severe disease emerging in Hong Kong. Journal of Infection, 2014, 69, 60-68.	3.3	34
137	Emergence in China of human disease due to avian influenza A(H10N8) â€“ Cause for concern?. Journal of Infection, 2014, 68, 205-215.	3.3	106
138	Avian-Origin Influenza A(H7N9) Infection in Influenza A(H7N9)â€“Affected Areas of China: A Serological Study. Journal of Infectious Diseases, 2014, 209, 265-269.	4.0	100
139	Novel Avian-Origin Human Influenza A(H7N9) Can Be Transmitted Between Ferrets via Respiratory Droplets. Journal of Infectious Diseases, 2014, 209, 551-556.	4.0	76
140	An important amino acid in nucleoprotein contributes to influenza A virus replication by interacting with polymerase PB2. Virology, 2014, 464-465, 11-20.	2.4	8
141	Proteomics study of Nâ€acetylcysteine response in H1N1â€infected cells by using mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 741-749.	1.5	6
142	Assessment of Antigen and Molecular Tests with Serial Specimens from a Patient with Influenza A(H7N9) Infection. Journal of Clinical Microbiology, 2014, 52, 2272-2274.	3.9	6
143	Dynamic behavior of lymphocyte subgroups correlates with clinical outcomes in human H7N9 infection. Journal of Infection, 2014, 69, 358-365.	3.3	15
144	A Study of Older People with Disability: Evidence from Two Cosmopolitan Cities. Ageing International, 2013, 38, 328-342.	1.3	0

#	Article	IF	Citations
145	Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. Journal of General Virology, 2013, 94, 2679-2690.	2.9	347
146	Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. Journal of Infection, 2013, 67, 606-616.	3.3	314
147	The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infectious Diseases, The, 2013, 13, 809-821.	9.1	129
148	Antigenicity and transmissibility of a novel clade 2.3.2.1 avian influenza H5N1 virus. Journal of General Virology, 2013, 94, 2616-2626.	2.9	12
149	Clinical, Virological, and Histopathological Manifestations of Fatal Human Infections by Avian Influenza A(H7N9) Virus. Clinical Infectious Diseases, 2013, 57, 1449-1457.	5.8	102
150	Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. Journal of Infection, 2013, 67, 130-140.	3.3	158
151	Genetic Characterization of Betacoronavirus Lineage C Viruses in Bats Reveals Marked Sequence Divergence in the Spike Protein of Pipistrellus Bat Coronavirus HKU5 in Japanese Pipistrelle: Implications for the Origin of the Novel Middle East Respiratory Syndrome Coronavirus. Journal of Virology, 2013, 87, 8638-8650.	3.4	225
152	Targeting of <scp>DICE1</scp> tumor suppressor by Epsteinâ€“Barr virusâ€encoded miRâ€BART3* microRNA in nasopharyngeal carcinoma. International Journal of Cancer, 2013, 133, 79-87.	5.1	86
153	Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet, The, 2013, 381, 1916-1925.	13.7	781
154	Perturbation of biogenesis and targeting of Epsteinâ€“Barr virus-encoded miR-BART3 microRNA by adenosine-to-inosine editing. Journal of General Virology, 2013, 94, 2739-2744.	2.9	22
155	Differential Cell Line Susceptibility to the Emerging Novel Human Betacoronavirus 2c EMC/2012: Implications for Disease Pathogenesis and Clinical Manifestation. Journal of Infectious Diseases, 2013, 207, 1743-1752.	4.0	195
156	Analytical Sensitivity of Seven Point-of-Care Influenza Virus Detection Tests and Two Molecular Tests for Detection of Avian Origin H7N9 and Swine Origin H3N2 Variant Influenza A Viruses. Journal of Clinical Microbiology, 2013, 51, 3160-3161.	3.9	45
157	Negotiating poverty from midlife to pre-old age: a longitudinal study on social assistance recipients in Shanghai. Asia Pacific Journal of Social Work and Development, 2013, 23, 285-298.	1.0	5
158	Enhanced IL-6/IL-6R Signaling Promotes Growth and Malignant Properties in EBV-Infected Premalignant and Cancerous Nasopharyngeal Epithelial Cells. PLoS ONE, 2013, 8, e62284.	2.5	69
159	The NS1 Protein of Influenza A Virus Interacts with Cellular Processing Bodies and Stress Granules through RNA-Associated Protein 55 (RAP55) during Virus Infection. Journal of Virology, 2012, 86, 12695-12707.	3.4	56
160	Draft Genome Sequence of the Novel Agarolytic Bacterium Aquimarina agarilytica ZC1. Journal of Bacteriology, 2012, 194, 2769-2769.	2.2	13
161	Establishment and Lineage Replacement of H6 Influenza Viruses in Domestic Ducks in Southern China. Journal of Virology, 2012, 86, 6075-6083.	3.4	77
162	A Triclade DNA Vaccine Designed on the Basis of a Comprehensive Serologic Study Elicits Neutralizing Antibody Responses against All Clades and Subclades of Highly Pathogenic Avian Influenza H5N1 Viruses. Journal of Virology, 2012, 86, 6970-6978.	3.4	45

#	Article	IF	Citations
163	Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3473-82.	7.1	127
164	Avian influenza A H5N1 virus: a continuous threat to humans. Emerging Microbes and Infections, 2012, 1, 1-12.	6.5	76
165	Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?. Journal of Infection, 2012, 65, 477-489.	3.3	147
166	Two-dimensional antigenic dendrogram and phylogenetic tree of avian influenza virus H5N1. FEMS Immunology and Medical Microbiology, 2012, 64, 205-211.	2.7	4
167	The 2008â€“2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Research, 2012, 93, 144-153.	4.1	21
168	The biology of EBV infection in human epithelial cells. Seminars in Cancer Biology, 2012, 22, 137-143.	9.6	99
169	Structural basis and sequence co-evolution analysis of the hemagglutinin protein of pandemic influenza A/H1N1 (2009) virus. Experimental Biology and Medicine, 2011, 236, 915-925.	2.4	15
170	Differential diagnosis of pandemic (H1N1) 2009 infection by detection of haemagglutinin with an enzyme-linked immunoassay. Clinical Microbiology and Infection, 2011, 17, 1574-1580.	6.0	16
171	Serological survey of antibodies to influenza A viruses in a group of people without a history of influenza vaccination. Clinical Microbiology and Infection, 2011, 17, 1347-1349.	6.0	15
172	Long-term evolution and transmission dynamics of swine influenza A virus. Nature, 2011, 473, 519-522.	27.8	219
173	Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. Virology, 2011, 409, 102-112.	2.4	40
174	Catalytic activity of matrix metalloproteinaseâ€19 is essential for tumor suppressor and antiâ€angiogenic activities in nasopharyngeal carcinoma. International Journal of Cancer, 2011, 129, 1826-1837.	5.1	52
175	Infection of immunocompromised patients by avian H9N2 influenza A virus. Journal of Infection, 2011, 62, 394-399.	3.3	91
176	Differences in Antibody Responses of Individuals with Natural Infection and Those Vaccinated against Pandemic H1N1 2009 Influenza. Vaccine Journal, 2011, 18, 867-873.	3.1	57
177	Properties and Therapeutic Efficacy of Broadly Reactive Chimeric and Humanized H5-Specific Monoclonal Antibodies against H5N1 Influenza Viruses. Antimicrobial Agents and Chemotherapy, 2011, 55, 1349-1357.	3.2	11
178	Novel Reassortment of Eurasian Avian-Like and Pandemic/2009 Influenza Viruses in Swine: Infectious Potential for Humans. Journal of Virology, 2011, 85, 10432-10439.	3.4	80
179	High Incidence of Severe Influenza among Individuals over 50 Years of Age. Vaccine Journal, 2011, 18, 1918-1924.	3.1	27
180	Clinical and Virological Factors Associated with Viremia in Pandemic Influenza A/H1N1/2009 Virus Infection. PLoS ONE, 2011, 6, e22534.	2.5	67

#	Article	IF	Citations
181	Influenza virus surveillance in migratory ducks and sentinel ducks at Poyang Lake, China. Influenza and Other Respiratory Viruses, 2011, 5, 65-8.	3.4	12
182	Pathogenicity and transmissibility of the pandemic H1N1 2009-related influenza viruses in mice, ferrets, and pigs. Influenza and Other Respiratory Viruses, 2011, 5, 82-4.	3.4	3
183	Antibody reactivity of conformational peptide mimics of a conserved H5N1 neutralization site in different fusion proteins. Archives of Virology, 2010, 155, 19-26.	2.1	1
184	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Investigational New Drugs, 2010, 28, 326-333.	2.6	40
185	A rapid test for the detection of influenza A virus including pandemic influenza A/H1N1 2009. Journal of Virological Methods, 2010, 167, 100-102.	2.1	19
186	Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antiviral Research, 2010, 87, 81-84.	4.1	8
187	Substitution of lysine at 627 position in PB2 protein does not change virulence of the 2009 pandemic H1N1 virus in mice. Virology, 2010, 401, 1-5.	2.4	55
188	Epsteinâ€Barr virus infection in immortalized nasopharyngeal epithelial cells: Regulation of infection and phenotypic characterization. International Journal of Cancer, 2010, 127, 1570-1583.	5.1	80
189	Identification of unusual truncated forms of nucleocapsid protein in MDCK cells infected by Avian influenza virus (H9N2). Proteomics, 2010, 10, 1875-1879.	2.2	4
190	Identification of influenza A nucleoprotein as an antiviral target. Nature Biotechnology, 2010, 28, 600-605.	17.5	234
191	Molecular Characterization ofIn VivoAdjuvant Activity in Ferrets Vaccinated against Influenza Virus. Journal of Virology, 2010, 84, 8369-8388.	3.4	45
192	Quasispecies of the D225G Substitution in the Hemagglutinin of Pandemic Influenza A(H1N1) 2009 Virus from Patients with Severe Disease in Hong Kong, China. Journal of Infectious Diseases, 2010, 201, 1517-1521.	4.0	99
193	Effect of Clinical and Virological Parameters on the Level of Neutralizing Antibody against Pandemic Influenza A Virus H1N1 2009. Clinical Infectious Diseases, 2010, 51, 274-279.	5.8	70
194	2009 Pandemic H1N1 Influenza Virus Replicates in Human Lung Tissues. Journal of Infectious Diseases, 2010, 201, 1522-1526.	4.0	15
195	Establishment of an H6N2 Influenza Virus Lineage in Domestic Ducks in Southern China. Journal of Virology, 2010, 84, 6978-6986.	3.4	83
196	GC/MS-based metabolomics reveals fatty acid biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus. Talanta, 2010, 83, 262-268.	5.5	81
197	Challenge and polymorphism analysis of the novel A (H1N1) influenza virus to normal animals. Virus Research, 2010, 151, 60-65.	2.2	11
198	Delayed Clearance of Viral Load and Marked Cytokine Activation in Severe Cases of Pandemic H1N1 2009 Influenza Virus Infection. Clinical Infectious Diseases, 2010, 50, 850-859.	5.8	403

#	Article	IF	Citations
199	D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Experimental Biology and Medicine, 2010, 235, 981-988.	2.4	99
200	Wild Type and Mutant 2009 Pandemic Influenza A (H1N1) Viruses Cause More Severe Disease and Higher Mortality in Pregnant BALB/c Mice. PLoS ONE, 2010, 5, e13757.	2.5	86
201	Detection of diverse astroviruses from bats in China. Journal of General Virology, 2009, 90, 883-887.	2.9	91
202	Dating the emergence of pandemic influenza viruses. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11709-11712.	7.1	387
203	Nuclear Factor 90 Negatively Regulates Influenza Virus Replication by Interacting with Viral Nucleoprotein. Journal of Virology, 2009, 83, 7850-7861.	3.4	62
204	Mutations in influenza virus replication and transcription: detection of amino acid substitutions in hemagglutinin of an avian influenza virus (H1N1). FASEB Journal, 2009, 23, 3377-3382.	0.5	8
205	Characterization of Avian Influenza Viruses A (H5N1) from Wild Birds, Hong Kong, 2004â€“2008. Emerging Infectious Diseases, 2009, 15, 402-407.	4.3	94
206	Serologic Survey of Pandemic (H1N1) 2009 Virus, Guangxi Province, China. Emerging Infectious Diseases, 2009, 15, 1849-1850.	4.3	77
207	Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China. Emerging Infectious Diseases, 2009, 15, 1970-1972.	4.3	92
208	Broad Cross-Protection against H5N1 Avian Influenza Virus Infection by Means of Monoclonal Antibodies that Map to Conserved Viral Epitopes. Journal of Infectious Diseases, 2009, 199, 49-58.	4.0	65
209	Identification of amino acid substitutions in avian influenza virus (H5N1) matrix protein 1 by using nanoelectrospray MS and MS/MS. Journal of the American Society for Mass Spectrometry, 2009, 20, 312-320.	2.8	11
210	Identification of amino acid substitutions in mutated peptides of nucleoprotein from avian influenza virus. Talanta, 2009, 78, 1492-1496.	5.5	3
211	Systemic infection of avian influenza A virus H5N1 subtype in humans. Human Pathology, 2009, 40, 735-739.	2.0	64
212	Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. Journal of Clinical Virology, 2009, 46, 325-330.	3.1	78
213	Peptide mimics of a conserved H5N1 avian influenza virus neutralization site. Biochemical Journal, 2009, 419, 133-139.	3.7	6
214	Proteomics analysis of differential expression of cellular proteins in response to avian H9N2 virus infection in human cells. Proteomics, 2008, 8, 1851-1858.	2.2	88
215	The development and genetic diversity of H5N1 influenza virus in China, 1996â€“2006. Virology, 2008, 380, 243-254.	2.4	140
216	Evaluation of a rapid test for detection of H5N1 avian influenza virus. Journal of Virological Methods, 2008, 154, 213-215.	2.1	21

#	Article	IF	Citations
217	Antigenic Profile of Avian H5N1 Viruses in Asia from 2002 to 2007. Journal of Virology, 2008, 82, 1798-1807.	3.4	100
218	Avian Metapneumovirus Subtype A in China and Subtypes A and B in Nigeria. Avian Diseases, 2008, 52, 502-506.	1.0	26
219	Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8091-8096.	7.1	280
220	Molecular Epidemiology of Chicken Anemia Virus (CAV) in Southeastern Chinese Live Birds Markets. Avian Diseases, 2008, 52, 68-73.	1.0	24
221	Genomic characterizations of bat coronaviruses (1A, 1B and HKU8) and evidence for co-infections in Miniopterus bats. Journal of General Virology, 2008, 89, 1282-1287.	2.9	92
222	Identification of the Progenitors of Indonesian and Vietnamese Avian Influenza A (H5N1) Viruses from Southern China. Journal of Virology, 2008, 82, 3405-3414.	3.4	81
223	Evolutionary Dynamics and Emergence of Panzootic H5N1 Influenza Viruses. PLoS Pathogens, 2008, 4, e1000161.	4.7	143
224	Avian Influenza A Virus (H5N1) Outbreaks, Kuwait, 2007. Emerging Infectious Diseases, 2008, 14, 958-961.	4.3	20
225	Molecular analysis of avian H7 influenza viruses circulating in Eurasia in 1999â€“2005: detection of multiple reassortant virus genotypes. Journal of General Virology, 2008, 89, 48-59.	2.9	44
226	Characterization of Low-Pathogenic H5 Subtype Influenza Viruses from Eurasia: Implications for the Origin of Highly Pathogenic H5N1 Viruses. Journal of Virology, 2007, 81, 7529-7539.	3.4	114
227	Neuraminidase Antibodies and H5N1: Geographic-Dependent Influenza Epidemiology Could Determine Cross-Protection against Emerging Strains. PLoS Medicine, 2007, 4, e212.	8.4	5
228	Establishment of Influenza A Virus (H6N1) in Minor Poultry Species in Southern China. Journal of Virology, 2007, 81, 10402-10412.	3.4	106
229	Detection of a Novel and Highly Divergent Coronavirus from Asian Leopard Cats and Chinese Ferret Badgers in Southern China. Journal of Virology, 2007, 81, 6920-6926.	3.4	127
230	Evolution and Molecular Epidemiology of H9N2 Influenza A Viruses from Quail in Southern China, 2000 to 2005. Journal of Virology, 2007, 81, 2635-2645.	3.4	163
231	Evolutionary Insights into the Ecology of Coronaviruses. Journal of Virology, 2007, 81, 4012-4020.	3.4	240
232	The Genesis and Evolution of H9N2 Influenza Viruses in Poultry from Southern China, 2000 to 2005. Journal of Virology, 2007, 81, 10389-10401.	3.4	214
233	Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respiratory Research, 2007, 8, 73.	3.6	250
234	Loop-Mediated Isothermal Amplification for Influenza A (H5N1) Virus. Emerging Infectious Diseases, 2007, 13, 899-901.	4.3	84

#	Article	IF	Citations
235	A model to control the epidemic of H5N1 influenza at the source. BMC Infectious Diseases, 2007, 7, 132.	2.9	37
236	Reliable universal RT-PCR assays for studying influenza polymerase subunit gene sequences from all 16 haemagglutinin subtypes. Journal of Virological Methods, 2007, 142, 218-222.	2.1	52
237	Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2845-2850.	7.1	557
238	Distribution of Amantadineâ€Resistant H5N1 Avian Influenza Variants in Asia. Journal of Infectious Diseases, 2006, 193, 1626-1629.	4.0	243
239	H5N1 Influenza Viruses in Lao People's Democratic Republic. Emerging Infectious Diseases, 2006, 12, 1593-1595.	4.3	20
240	H5N1 Outbreaks and Enzootic Influenza. Emerging Infectious Diseases, 2006, 12, 3-8.	4.3	344
241	Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology, 2006, 350, 258-268.	2.4	212
242	Coronaviruses in bent-winged bats (Miniopterus spp.). Journal of General Virology, 2006, 87, 2461-2466.	2.9	68
243	Avian influenza H5N1 in viverrids: implications for wildlife health and conservation. Proceedings of the Royal Society B: Biological Sciences, 2006, 273, 1729-1732.	2.6	80
244	Contribution of C/EBP Proteins to Epstein-Barr Virus Lytic Gene Expression and Replication in Epithelial Cells. Journal of Virology, 2006, 80, 1098-1109.	3.4	47
245	Prevalence and Genetic Diversity of Coronaviruses in Bats from China. Journal of Virology, 2006, 80, 7481-7490.	3.4	301
246	Emergence and predominance of an H5N1 influenza variant in China. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16936-16941.	7.1	279
247	H5N1 virus outbreak in migratory waterfowl. Nature, 2005, 436, 191-192.	27.8	708
248	SARS-CoV Infection in a Restaurant from Palm Civet. Emerging Infectious Diseases, 2005, 11, 1860-1865.	4.3	283
249	Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003. Journal of Clinical Microbiology, 2005, 43, 5760-5767.	3.9	561
250	Regulation of Expression of the Epstein-Barr Virus BamHI-A Rightward Transcripts. Journal of Virology, 2005, 79, 1724-1733.	3.4	61
251	Generation of recombinant influenza A virus without M2 ion-channel protein by introduction of a point mutation at the 5â€² end of the viral intron. Journal of General Virology, 2005, 86, 1447-1454.	2.9	23
252	Clinical and Molecular Epidemiological Features of Coronavirus HKU1â€“Associated Communityâ€Acquired Pneumonia. Journal of Infectious Diseases, 2005, 192, 1898-1907.	4.0	221

#	Article	IF	Citations
253	Resistance to anti-influenza agents. Lancet, The, 2005, 366, 1139-1140.	13.7	25
254	Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antiviral Therapy, 2005, 10, 393-403.	1.0	36
255	Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus. Antiviral Therapy, 2005, 10, 393-403.	1.0	63
256	Early Activation of the Kaposi's Sarcoma-Associated Herpesvirus RTA, RAP, and MTA Promoters by the Tetradecanoyl Phorbol Acetate-Induced AP1 Pathway. Journal of Virology, 2004, 78, 4248-4267.	3.4	100
257	CCAAT/Enhancer Binding Protein Î± Binds to the Epstein-Barr Virus (EBV) ZTA Protein through Oligomeric Interactions and Contributes to Cooperative Transcriptional Activation of the ZTA Promoter through Direct Binding to the ZII and ZIIIB Motifs during Induction of the EBV Lytic Cycle. Journal of Virology, 2004, 78, 4847-4865.	3.4	40
258	Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature, 2004, 430, 209-213.	27.8	1,147
259	A Positive Autoregulatory Loop of LMP1 Expression and STAT Activation in Epithelial Cells Latently Infected with Epstein-Barr Virus. Journal of Virology, 2003, 77, 4139-4148.	3.4	143
260	CCAAT/Enhancer Binding Protein Î± Interacts with ZTA and Mediates ZTA-Induced p21 CIP-1 Accumulation and G 1 Cell Cycle Arrest during the Epstein-Barr Virus Lytic Cycle. Journal of Virology, 2003, 77, 1481-1500.	3.4	73
261	Cell Cycle Arrest by Kaposi's Sarcoma-Associated Herpesvirus Replication-Associated Protein Is Mediated at both the Transcriptional and Posttranslational Levels by Binding to CCAAT/Enhancer-Binding Protein Î± and p21 CIP-1. Journal of Virology, 2003, 77, 8893-8914.	3.4	54
262	Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-Â. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10683-10688.	7.1	76
263	Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. International Journal of Cancer, 2002, 97, 489-492.	5.1	59
264	Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus. Oncogene, 2002, 21, 825-835.	5.9	25
265	Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus. Oncogene, 2002, 21, 825-835.	5.9	0
266	Linkage between STAT Regulation and Epstein-Barr Virus Gene Expression in Tumors. Journal of Virology, 2001, 75, 2929-2937.	3.4	132
267	Epstein-Barr Virus Bam HI-A Rightward Transcript-Encoded RPMS Protein Interacts with the CBF1-Associated Corepressor CIR To Negatively Regulate the Activity of EBNA2 and NotchIC. Journal of Virology, 2001, 75, 2946-2956.	3.4	59
268	Expression of Epstein-Barr Virus BamHI-A Rightward Transcripts in Latently Infected B Cells From Peripheral Blood. Blood, 1999, 93, 3026-3032.	1.4	74
269	The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9339-9344.	7.1	64
270	Expression of Epstein-Barr Virus BamHI-A Rightward Transcripts in Latently Infected B Cells From Peripheral Blood. Blood, 1999, 93, 3026-3032.	1.4	29

#	Article	IF	Citations
271	Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology, 1992, 191, 193-201.	2.4	91
272	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 0, , .	27.8	72